See more : Aero Win Technology Corporation (8222.TW) Income Statement Analysis – Financial Results
Complete financial analysis of iCAD, Inc. (ICAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iCAD, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Morgan Stanley Emerging Markets Debt Fund, Inc. (MSD) Income Statement Analysis – Financial Results
- Shanghai XNG Holdings Limited (3666.HK) Income Statement Analysis – Financial Results
- Endymed Ltd (ENDY.TA) Income Statement Analysis – Financial Results
- Green Visor Financial Technology Acquisition Corp. I (GVCIW) Income Statement Analysis – Financial Results
- Fiera Capital Corporation (FRRPF) Income Statement Analysis – Financial Results
iCAD, Inc. (ICAD)
About iCAD, Inc.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.32M | 27.94M | 33.64M | 29.70M | 31.34M | 25.62M | 28.10M | 26.34M | 41.55M | 43.92M | 33.07M | 28.28M | 28.65M | 24.58M | 28.11M | 37.49M | 26.61M | 19.72M | 19.77M | 23.31M | 6.52M | 5.00M | 4.84M | 7.79M | 6.70M | 5.30M | 7.90M | 11.30M | 20.60M | 24.40M | 20.60M | 23.00M | 11.90M | 21.70M | 18.40M | 11.20M | 2.70M |
| Cost of Revenue | 2.78M | 8.13M | 9.40M | 8.34M | 7.11M | 6.19M | 9.93M | 7.82M | 12.20M | 12.70M | 9.98M | 8.24M | 8.63M | 3.15M | 4.62M | 6.18M | 5.26M | 4.29M | 4.64M | 6.53M | 2.94M | 5.16M | 3.94M | 5.27M | 4.50M | 3.40M | 4.90M | 7.10M | 12.00M | 13.50M | 11.70M | 10.40M | 6.90M | 12.10M | 12.10M | 7.60M | 7.10M |
| Gross Profit | 14.54M | 19.81M | 24.24M | 21.35M | 24.23M | 19.43M | 18.18M | 18.52M | 29.35M | 31.23M | 23.09M | 20.03M | 20.03M | 21.43M | 23.49M | 31.32M | 21.36M | 15.43M | 15.13M | 16.78M | 3.58M | -161.46K | 898.89K | 2.52M | 2.20M | 1.90M | 3.00M | 4.20M | 8.60M | 10.90M | 8.90M | 12.60M | 5.00M | 9.60M | 6.30M | 3.60M | -4.40M |
| Gross Profit Ratio | 83.94% | 70.90% | 72.07% | 71.90% | 77.30% | 75.84% | 64.68% | 70.31% | 70.63% | 71.09% | 69.81% | 70.84% | 69.90% | 87.20% | 83.56% | 83.53% | 80.25% | 78.24% | 76.55% | 71.97% | 54.88% | -3.23% | 18.59% | 32.38% | 32.84% | 35.85% | 37.97% | 37.17% | 41.75% | 44.67% | 43.20% | 54.78% | 42.02% | 44.24% | 34.24% | 32.14% | -162.96% |
| Research & Development | 5.16M | 8.59M | 9.19M | 8.11M | 9.27M | 9.45M | 9.33M | 9.52M | 9.16M | 8.16M | 7.69M | 7.77M | 10.79M | 6.60M | 7.22M | 7.12M | 4.50M | 5.26M | 4.79M | 4.83M | 2.38M | 1.63M | 751.47K | 709.60K | 800.00K | 1.10M | 1.40M | 2.40M | 2.80M | 2.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.32M | 11.23M | 10.41M | 9.12M | 7.44M | 9.12M | 7.88M | 7.68M | 8.79M | 8.04M | 6.74M | 6.97M | 10.08M | 9.92M | 7.35M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.74M | 13.69M | 15.14M | 13.31M | 13.63M | 8.69M | 10.50M | 10.18M | 12.40M | 12.47M | 10.43M | 10.71M | 13.68M | 11.49M | 11.04M | 11.96M | 10.78M | 9.23M | 8.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.06M | 24.93M | 25.54M | 22.43M | 21.08M | 17.81M | 18.38M | 17.85M | 21.19M | 20.51M | 17.17M | 17.67M | 23.76M | 21.40M | 18.39M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 5.10M | 8.00M | 7.20M | 8.80M | 9.80M | 7.70M | 7.90M | 0.00 |
| Other Expenses | 0.00 | 224.00K | 240.00K | 199.00K | 276.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | -4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| Operating Expenses | 22.23M | 33.74M | 34.98M | 30.74M | 30.62M | 27.56M | 28.16M | 28.49M | 31.99M | 30.41M | 24.86M | 25.44M | 30.39M | 28.00M | 25.61M | 26.55M | 22.46M | 21.87M | 19.89M | 17.04M | 11.66M | 9.21M | 3.44M | 4.22M | 4.40M | 4.80M | 6.10M | 9.60M | 10.80M | 9.60M | 9.30M | 8.40M | 9.50M | 11.80M | 9.50M | 8.50M | 500.00K |
| Cost & Expenses | 25.01M | 41.87M | 44.37M | 39.09M | 37.74M | 33.75M | 38.09M | 36.31M | 44.19M | 43.11M | 34.84M | 33.69M | 39.02M | 31.15M | 30.23M | 32.73M | 27.72M | 26.16M | 24.52M | 23.58M | 14.60M | 14.37M | 7.38M | 9.49M | 8.90M | 8.20M | 11.00M | 16.70M | 22.80M | 23.10M | 21.00M | 18.80M | 16.40M | 23.90M | 21.60M | 16.10M | 7.60M |
| Interest Income | 729.00K | 213.00K | 15.00K | 97.00K | 344.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | 24.00K | 73.27K | 119.10K | 106.03K | 74.15K | 102.96K | 127.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.00K | 10.00K | 141.00K | 476.00K | 784.00K | 504.00K | 124.00K | 63.00K | 650.00K | 2.64M | 3.28M | 3.42M | 419.00K | 269.00 | 9.33K | 280.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 409.00K | 521.00K | 557.00K | 578.00K | 673.00K | 708.00K | 1.49M | 2.31M | 3.35M | 3.53M | 2.43M | 2.80M | 3.17M | 1.64M | 1.92M | 1.84M | 1.70M | 1.66M | 1.63M | 1.34M | 667.89K | 389.88K | 486.14K | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| EBITDA | -6.57M | -9.50M | -10.55M | -16.52M | -12.05M | -7.31M | -12.66M | -7.67M | -28.43M | 4.34M | -1.77M | -3.12M | -34.42M | -4.58M | -80.66K | 6.71M | 598.07K | -4.67M | -3.00M | 1.07M | -7.42M | -8.98M | -2.05M | -1.07M | -1.60M | -2.20M | -1.80M | -3.20M | -200.00K | 2.90M | 900.00K | 5.40M | -3.80M | -200.00K | -1.40M | -4.30M | -4.40M |
| EBITDA Ratio | -37.91% | -47.38% | -30.20% | -54.48% | -38.45% | -30.30% | -30.16% | -29.06% | 1.76% | 9.97% | 2.04% | -9.13% | -25.02% | -19.76% | -7.55% | 17.62% | 2.25% | -24.21% | -15.79% | 4.60% | -113.73% | -179.60% | -42.49% | -13.75% | -23.88% | -41.51% | -55.70% | -28.32% | 12.14% | 11.89% | 4.37% | 23.48% | -31.93% | -0.92% | -7.61% | -38.39% | -44.44% |
| Operating Income | -7.69M | -13.93M | -10.73M | -9.39M | -6.40M | -8.13M | -14.17M | -9.97M | -30.08M | 815.00K | -1.78M | -5.41M | -37.19M | -6.57M | -2.12M | 4.77M | -1.10M | -6.44M | -4.75M | -267.22K | -8.08M | -9.37M | -2.54M | -1.70M | -2.20M | -2.90M | -3.10M | -5.40M | -2.20M | 1.30M | -400.00K | 4.20M | -4.50M | -2.20M | -3.20M | -4.90M | -4.90M |
| Operating Income Ratio | -44.40% | -49.85% | -31.90% | -31.61% | -20.41% | -31.73% | -50.42% | -37.85% | -72.39% | 1.86% | -5.37% | -19.14% | -129.81% | -26.74% | -7.55% | 12.71% | -4.15% | -32.65% | -24.05% | -1.15% | -123.98% | -187.40% | -52.54% | -21.76% | -32.84% | -54.72% | -39.24% | -47.79% | -10.68% | 5.33% | -1.94% | 18.26% | -37.82% | -10.14% | -17.39% | -43.75% | -181.48% |
| Total Other Income/Expenses | 699.00K | 164.00K | -512.00K | -8.18M | -7.11M | -845.00K | -106.00K | -53.00K | -2.35M | -1.67M | -5.71M | -3.92M | -395.00K | 348.27K | 109.77K | -174.60K | -434.73K | -199.28K | -3.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.60M | 0.00 | -2.70M | -300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.20M |
| Income Before Tax | -6.99M | -13.77M | -11.24M | -17.57M | -13.51M | -8.98M | -14.27M | -10.02M | -32.43M | -856.00K | -7.48M | -9.33M | -37.59M | -6.22M | -2.01M | 4.59M | -1.54M | -6.64M | -4.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00K | 0.00 | -4.90M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.10M |
| Income Before Tax Ratio | -40.36% | -49.28% | -33.43% | -59.17% | -43.10% | -35.03% | -50.79% | -38.06% | -78.05% | -1.95% | -22.63% | -33.00% | -131.18% | -25.33% | -7.15% | 12.25% | -5.78% | -33.66% | -24.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6.33% | 0.00% | -23.79% | 4.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -300.00% |
| Income Tax Expense | 20.00K | -116.00K | 1.00K | 38.00K | 43.00K | 42.00K | -18.00K | 76.00K | 16.00K | 153.00K | 126.00K | 43.00K | 419.00K | 0.00 | -43.57K | 235.00K | 0.00 | 0.00 | 0.00 | 561.04K | 114.66K | 48.17K | 80.11K | 132.01K | 1.80M | 500.00K | -2.30M | 700.00K | 3.10M | 100.00K | 400.00K | 400.00K | 500.00K | 100.00K | 300.00K | 400.00K | 3.70M |
| Net Income | -4.85M | -13.66M | -11.25M | -17.61M | -13.55M | -9.02M | -14.26M | -10.10M | -32.45M | -1.01M | -7.61M | -9.37M | -37.59M | -6.22M | -1.97M | 4.36M | -1.54M | -6.64M | -4.76M | -828.26K | -8.20M | -9.42M | -2.62M | -1.83M | -4.00M | -3.40M | -800.00K | -6.10M | -5.30M | 900.00K | -800.00K | 3.80M | -5.00M | -2.30M | -3.50M | -5.30M | -8.60M |
| Net Income Ratio | -27.99% | -48.87% | -33.43% | -59.30% | -43.24% | -35.19% | -50.73% | -38.34% | -78.08% | -2.30% | -23.01% | -33.15% | -131.18% | -25.33% | -7.00% | 11.62% | -5.78% | -33.66% | -24.07% | -3.55% | -125.74% | -188.36% | -54.20% | -23.45% | -59.70% | -64.15% | -10.13% | -53.98% | -25.73% | 3.69% | -3.88% | 16.52% | -42.02% | -10.60% | -19.02% | -47.32% | -318.52% |
| EPS | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.44 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| EPS Diluted | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.40 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| Weighted Avg Shares Out | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.68M | 16.34M | 15.93M | 15.67M | 14.10M | 10.84M | 10.77M | 10.91M | 9.17M | 9.10M | 8.34M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 1.81M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
| Weighted Avg Shares Out (Dil) | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.69M | 16.34M | 15.93M | 15.69M | 14.10M | 10.84M | 10.80M | 10.91M | 9.17M | 9.10M | 8.55M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 2.00M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
iCAD, Inc. (ICAD) Q2 2023 Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Jessica Burns – Head-Global Communications Dana Brown – President and Chief Executive Officer Eric Lonnqvist – Chief Financial Officer Conference Call Participants Per...
iCAD Reports Financial Results for Second Quarter Ended June 30, 2023
NASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2023.
5 AI Stocks That Could Turn $50,000 Into $1 Million
This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.
iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023
NASHUA, N.H., July 31, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will release financial results for the second quarter of 2023 and host a...
If You Can Only Buy One Tech Stock, It Better Be One of These 7 Names
Remember The Game of Thrones? If I had to describe investing in stocks in only four words, it would be “The Game of Trends.
iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation's Largest Radiology Practice
Agreement positions iCAD as Radiology Partners' breast AI provider, expanding potential for iCAD's technology to reach millions of women in the U.S. Agreement positions iCAD as Radiology Partners' breast AI provider, expanding potential for iCAD's technology to reach millions of...
iCAD's “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic
Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD's Breast AI Suite helps her detect the breast cancers radiologists fear most Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD's Breast AI Suite helps her detect...
iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting
Company's ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilities Company's ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilities
7 Stocks to Target for Triple-Digit Returns in 2023
The U.S. government just revised Q1 GDP to 2% from 1.3%, which tells us, despite the frantic warnings of many bearish economists, a recession is not likely. In addition, the labor market remains strong, as new applications for unemployment benefits sank...
CEO Shuffle: 7 Stocks That Could Gain Momentum From New Leadership
New CEOs can breathe new life into a company by launching new initiatives, hiring more effective managers, and/or entering new markets. One great example is General Electric.
Source: https://incomestatements.info
Category: Stock Reports